Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases
AssigneeYeda Research and Development Co. Ltd.
InventorsMoshit Lindzen, Yosef Yarden
Life of this patent
Estimating the term…
Abstract
A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed.
Claims6
A method of alleviating the progression of an ErbB-family expressing cancer in a subject in need thereof, the method comprising:
- (a) administering a therapeutically effective amount of a first antibody or fragment thereof having the complementarity-determining regions (CDRs) of the monocloncal antibody deposit number CNCM I-4292 (Clone No. 551.6.103), deposited at the Collection Nationale De Cultures De Microorganismes (CNCM);
- and
- (b) administering a therapeutically effective amount of a second antibody or fragment thereof having the CDRs of the monoclonal antibody deposit number CNCM I-4291 (Clone No. 898.47), deposited at CNCM, thereby alleviating the progression of an ErbB-family expressing cancer in said subject.
Dependencies are inferred from the claim text.